PubMed Health⌕ Search

Biomedical subjects

J Braz Nogueira

Publications and source records attributed to J Braz Nogueira.

9 recordsLinked to original sources
PubMed2005

Genetics of left ventricular hypertrophy and its regression.

Genetics of left ventricularophy and its regression The importance of left ventricular hypertrophy (LVH) in hypertension is well established. The development of LVH results from the interaction of genetic, hemodynamic, neurohumoral and environmental factors. In this review we describe the principal genetic alterations of cardiac hypertrophy and the genetic polymorphisms that are most consistently related to its development and particularly to the therapeutic induction of regression. The identification of a particular genetic profile could, in the future, help to predict the regression of left ventricular hypertrophy in response to different antihypertensive drugs.

Humans↗
PubMed2004

Antihypertensive pharmacogenetics.

Essential hypertension is a complex disease in which multiple genetic and environmental factors interact to produce the phenotype. The genetic contribution to blood pressure variations is estimated to range from 30% to 50%. In this review we describe some of the genes and genetic polymorphisms that have been most consistently related to blood pressure elevation and also the importance of pharmacogenetics and the emerging evidence of genetic influences on antihypertensive drug responses, with the potential for getting the right drug into the right patient based on the individual genetic profile.

Antihypertensive Agents↗
PubMed1980

Erythrocyte acetylcholinesterase in essential hypertension.

Red cell acetylcholinesterase activity (AChE) has been studied in 58 patients suffering from essential hypertension; diastolic blood pressure values were about 130 mm or higher in 45 patients (group A) and lower in 13 (group B). The very significant increase (p < 0.001) of AChE activity in group A has been forced by the severity of systemic lesions. Meanwhile, the AChE values have been slightly increased, but not statistically significant in the patients of group B. These results are supporting the hypothesis that the blood pressure control can be mediated or normalized, at least in part, by cholinergic mechanisms.

Acetylcholinesterase↗
PubMedDate not supplied

Regression of left ventricular hypertrophy in hypertension--does it reduce cardiovascular risk?

Left ventricular hypertrophy (LVH) is a well-known cardiovascular risk factor. Left ventricular mass reduction following anti-hypertensive treatment has also been demonstrated. However, few prospective and systematic clinical trials have analyzed whether regression of LVH is associated with improved prognosis. Two recently published LIFE substudies consistently show that the greater the reduction of LVH, assessed by ECG or by echocardiography in the setting of a prospective trial of anti-hypertensive treatment, the greater the reduction in cardiovascular event rates, independent of treatment modality and of decreases in blood pressure. These results support LVH regression as a therapeutic target in hypertension.

Antihypertensive Agents↗